LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis GBX 145 +1.50 (+1.05%) As of 11:50 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About Diaceutics Stock (LON:DXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Diaceutics alerts:Sign Up Key Stats Today's Range 143.50▼ 15050-Day Range 127▼ 154.9652-Week Range 125▼ 180Volume86,580 shsAverage Volume207,731 shsMarket Capitalization£122.71 millionP/E Ratio1,318.18Dividend YieldN/APrice TargetGBX 215Consensus RatingBuy Company Overview At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®. Read More Diaceutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreDXRX MarketRank™: Diaceutics scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingDiaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialDiaceutics has a consensus price target of GBX 215, representing about 48.3% upside from its current price of GBX 145.Amount of Analyst CoverageDiaceutics has only been the subject of 1 research reports in the past 90 days.Read more about Diaceutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Diaceutics is 1,318.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 42.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Diaceutics is 1,318.18, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 212.23.Price to Book Value per Share RatioDiaceutics has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DXRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDiaceutics does not currently pay a dividend.Dividend GrowthDiaceutics does not have a long track record of dividend growth. News and Social Media0.9 / 5News SentimentN/A News SentimentDiaceutics has a news sentiment score of -0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Diaceutics this week, compared to 0 articles on an average week. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Diaceutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.33% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions32.64% of the stock of Diaceutics is held by institutions.Read more about Diaceutics' insider trading history. Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXRX Stock News HeadlinesDiaceutics and PCC Launch NGS Study to Boost Confidence in Cancer DiagnosticsAugust 20, 2026 | tipranks.comDiaceutics boosts employee share incentives and updates total voting rightsAugust 4, 2026 | tipranks.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 26 at 1:00 AM | Porter & Company (Ad)Diaceutics Issues Shares Under Employee Incentive Schemes in Latest Block Listing UpdateApril 7, 2026 | tipranks.comDiaceutics Executes Routine Management Share Purchases Under Incentive Plan With No Change to Share CapitalApril 1, 2026 | tipranks.comDiaceutics Issues New Shares to Trust as PDMRs Participate in Incentive PlanFebruary 3, 2026 | tipranks.comDiaceutics PLC Expands Employee Share Incentive PlanNovember 28, 2025 | tipranks.comDiaceutics PLC Enhances Employee Engagement with Share Incentive PlanNovember 4, 2025 | tipranks.comSee More Headlines DXRX Stock Analysis - Frequently Asked Questions How have DXRX shares performed this year? Diaceutics' stock was trading at GBX 128 at the beginning of the year. Since then, DXRX stock has increased by 13.3% and is now trading at GBX 145. How were Diaceutics' earnings last quarter? Diaceutics PLC (LON:DXRX) announced its quarterly earnings results on Tuesday, May, 26th. The company reported $11.00 earnings per share for the quarter. The company had revenue of $38.44 million for the quarter. Diaceutics had a trailing twelve-month return on equity of 0.25% and a net margin of 0.25%. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Diaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR). Company Calendar Last Earnings5/26/2026Today8/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolLON:DXRX CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Price Target for DiaceuticsGBX 215 High Price TargetGBX 215 Low Price TargetGBX 215 Potential Upside/Downside+48.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX 0.11 Trailing P/E Ratio1,318.18 Forward P/E Ratio143.45 P/E GrowthN/ANet Income-£2.84 million Net Margins0.25% Pretax MarginN/A Return on Equity0.25% Return on Assets-6.06% Debt Debt-to-Equity Ratio2.85 Current Ratio3.43 Quick Ratio9.92 Sales & Book Value Annual Sales£38.44 million Price / Sales3.19 Cash FlowGBX 46.48 per share Price / Cash Flow3.12 Book ValueGBX 45.87 per share Price / Book3.16Miscellaneous Outstanding Shares84,629,000Free FloatN/AMarket Cap£122.71 million OptionableNot Optionable Beta0.89 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (LON:DXRX) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredBuy this stock todayMost tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
